Autoimmune Diseases
Welcome,         Profile    Billing    Logout  
 293 Companies   491 Products   491 Products   198 Mechanisms of Action   26 Trials   7806 News 


12345678910111213...156157»
  • ||||||||||  Trial primary completion date:  RelSEP: Lorraine Registry of Multiple Sclerosis (clinicaltrials.gov) -  Feb 8, 2023   
    P=N/A,  N=6000, Recruiting, 
    N=52 --> 33 Trial primary completion date: Jan 2020 --> Jan 2030
  • ||||||||||  Vyvgart (efgartigimod alfa-fcab) / argenx, Broteio
    Trial completion, Trial completion date, Trial primary completion date:  A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP (clinicaltrials.gov) -  May 6, 2019   
    P2,  N=38, Completed, 
    Trial primary completion date: Jan 2020 --> Jan 2030 Recruiting --> Completed | Trial completion date: Nov 2018 --> Apr 2019 | Trial primary completion date: Aug 2018 --> Apr 2019
  • ||||||||||  Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    Trial completion:  MENTOR: MEmbranous Nephropathy Trial Of Rituximab (clinicaltrials.gov) -  Apr 30, 2019   
    P2/3,  N=130, Completed, 
    Recruiting --> Completed | Trial completion date: Nov 2018 --> Apr 2019 | Trial primary completion date: Aug 2018 --> Apr 2019 Active, not recruiting --> Completed
  • ||||||||||  Trial completion:  Implantology and Sj (clinicaltrials.gov) -  Apr 30, 2019   
    P=N/A,  N=120, Completed, 
    N=86 --> 40 | Recruiting --> Terminated; interim anlaysis failed: palifermin does not promote thymopoeisis after alemtuzumab Recruiting --> Completed
  • ||||||||||  Trial completion:  Rouxbe Pilot for MS (clinicaltrials.gov) -  Apr 29, 2019   
    P=N/A,  N=15, Completed, 
    Recruiting --> Completed Recruiting --> Completed
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  REMINDRA: REMission INDuction in Very Early Rheumatoid Arthritis (clinicaltrials.gov) -  Apr 29, 2019   
    P4,  N=53, Terminated, 
    Recruiting --> Completed N=267 --> 53 | Trial completion date: Nov 2023 --> Jan 2019 | Recruiting --> Terminated | Trial primary completion date: Nov 2022 --> Jan 2019; low recruitment rate
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  A Study of Flt3-Ligand Levels in Sjögrens Syndrome (clinicaltrials.gov) -  Apr 24, 2019   
    P=N/A,  N=30, Completed, 
    Active, not recruiting --> Completed | N=79 --> 200 Recruiting --> Completed | N=50 --> 30 | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Dec 2019 --> Apr 2019
  • ||||||||||  Tysabri (natalizumab) / Biogen, Royalty
    Trial completion, Enrollment change:  IIT12: Validation of a Laboratory Test Measuring Natalizumab (Tysabri®) Serum Levels in MS (clinicaltrials.gov) -  Apr 24, 2019   
    P=N/A,  N=109, Completed, 
    Recruiting --> Completed | N=50 --> 30 | Trial completion date: Dec 2019 --> Apr 2019 | Trial primary completion date: Dec 2019 --> Apr 2019 Recruiting --> Completed | N=500 --> 109
  • ||||||||||  Keytruda (pembrolizumab) / Merck (MSD), Opdivo (nivolumab) / Ono Pharma, BMS, Yervoy (ipilimumab) / Ono Pharma, BMS
    Trial completion, Enrollment change, Checkpoint inhibition, Metastases:  CHECKAUTO: Immune Checkpoint Inhibitors and Pre-existing Autoimmune Diseases (clinicaltrials.gov) -  Apr 22, 2019   
    P=N/A,  N=112, Completed, 
    Recruiting --> Completed | Trial completion date: Jul 2019 --> Apr 2019 Recruiting --> Completed | N=50 --> 112
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Outcomes Study of the TM Humeral Stem Used in Primary, Total or Hemi Shoulder Arthroplasty (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=67, Terminated, 
    Terminated --> Withdrawn N=120 --> 67 | Trial completion date: Dec 2024 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Dec 2018; Business decision was made to remove the CE mark from this product, thus prompting the closing of this study.
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  Resistance Exercise in Rheumatic Disease (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=15, Terminated, 
    N=120 --> 67 | Trial completion date: Dec 2024 --> Dec 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Dec 2018; Business decision was made to remove the CE mark from this product, thus prompting the closing of this study. N=10 --> 15 | Trial completion date: Jun 2019 --> Dec 2018 | Suspended --> Terminated | Trial primary completion date: Jun 2019 --> Dec 2018; Funding ended.
  • ||||||||||  Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  PRESSRA: The PRESS RA: Protein and Resistance Exercise Supplementation Study for Rheumatoid Arthritis (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=23, Terminated, 
    Active, not recruiting --> Completed N=50 --> 23 | Trial completion date: Dec 2018 --> Jul 2018 | Suspended --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2018; Funding ended
  • ||||||||||  Hizentra (human immune globulin subcutaneous 20%) / CSL Behring
    Phase classification:  SIMM: Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis (clinicaltrials.gov) -  Apr 20, 2019   
    P1,  N=4, Terminated, 
    N=50 --> 23 | Trial completion date: Dec 2018 --> Jul 2018 | Suspended --> Terminated | Trial primary completion date: Dec 2018 --> Jul 2018; Funding ended Phase classification: P=N/A --> P1
  • ||||||||||  Biomarker, Trial completion:  Salivary Biomarkers for Sj (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=420, Completed, 
    Phase classification: P=N/A --> P1 Active, not recruiting --> Completed
  • ||||||||||  Enrollment change, Trial termination:  Massage Therapy in Juvenile Idiopathic Arthritis (clinicaltrials.gov) -  Apr 20, 2019   
    P=N/A,  N=6, Terminated, 
    Active, not recruiting --> Completed N=30 --> 6 | Recruiting --> Terminated; Inability to recruit study participants
  • ||||||||||  Biomarker, Trial completion date, Trial termination, Trial primary completion date:  BioACG: Biomarkers in Giant Cells Arteritis (clinicaltrials.gov) -  Apr 18, 2019   
    P=N/A,  N=100, Terminated, 
    Active, not recruiting --> Completed Trial completion date: Oct 2019 --> Jan 2019 | Recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Jan 2019; recruitment failure
  • ||||||||||  Trial completion, Adherence:  SMART T1D: Group Education Curriculum for Older Teens With Type 1 Diabetes (clinicaltrials.gov) -  Apr 17, 2019   
    P=N/A,  N=40, Completed, 
    Recruiting --> Completed | Trial completion date: Jan 2020 --> Jan 2019 | Trial primary completion date: Jan 2020 --> Jan 2019 Active, not recruiting --> Completed
  • ||||||||||  Biomarker, Trial completion:  A Pilot Study of Biomarkers of Stress in Youth Who Use Teens.Connect (clinicaltrials.gov) -  Apr 2, 2019   
    P=N/A,  N=29, Completed, 
    Trial completion date: Dec 2019 --> Feb 2019 | Recruiting --> Terminated | Trial primary completion date: Dec 2019 --> Feb 2019; Lack of trial population, unable to recruit subjects Active, not recruiting --> Completed
  • ||||||||||  staphylococcal protein A (PRTX-100) / Protalex
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  PRTX-100-203 Open-Label, Dose Escalation Study in Adult Patients With ITP (clinicaltrials.gov) -  Mar 25, 2019   
    P1b,  N=15, Terminated, 
    Active, not recruiting --> Completed | Trial completion date: Jun 2019 --> Dec 2018 | Trial primary completion date: Jun 2019 --> Dec 2018 N=30 --> 15 | Trial completion date: Dec 2018 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Enough data has been collected to allow analysis of the safety profile and risk-benefit.
  • ||||||||||  Promacta (eltrombopag) / Novartis
    Enrollment change:  Eltrombopag and the Bcl-extra-large (xL) Pathway in Idiopathic Thrombocytopenic Purpura (ITP) (clinicaltrials.gov) -  Mar 18, 2019   
    P2,  N=20, Completed, 
    N=30 --> 15 | Trial completion date: Dec 2018 --> May 2018 | Recruiting --> Terminated | Trial primary completion date: Dec 2018 --> May 2018; Enough data has been collected to allow analysis of the safety profile and risk-benefit. N=12 --> 20
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  Teleconsultation in Type 1 Diabetes Mellitus (clinicaltrials.gov) -  Mar 15, 2019   
    P=N/A,  N=150, Completed, 
    Active, not recruiting --> Completed | Trial completion date: Nov 2017 --> Feb 2019 | Trial primary completion date: Oct 2017 --> Feb 2019 Recruiting --> Completed | Trial completion date: Jul 2017 --> Sep 2018 | Trial primary completion date: Jun 2017 --> Jul 2018
  • ||||||||||  Trial completion, Enrollment change, Trial completion date, Trial primary completion date, HEOR:  LUPP: Pilot Study to Investigate Contemplative Intervention in Lupus Patients (clinicaltrials.gov) -  Mar 14, 2019   
    P=N/A,  N=30, Completed, 
    Recruiting --> Completed | Trial completion date: Jul 2017 --> Sep 2018 | Trial primary completion date: Jun 2017 --> Jul 2018 Recruiting --> Completed | N=44 --> 30 | Trial completion date: Feb 2018 --> Jun 2018 | Trial primary completion date: Oct 2017 --> Jun 2018
  • ||||||||||  Trial completion:  Three-dimensional Measurements of Diabetic Foot Ulcers (clinicaltrials.gov) -  Mar 13, 2019   
    P=N/A,  N=150, Completed, 
    Recruiting --> Completed | N=44 --> 30 | Trial completion date: Feb 2018 --> Jun 2018 | Trial primary completion date: Oct 2017 --> Jun 2018 Active, not recruiting --> Completed
  • ||||||||||  Trial completion, Trial completion date, Trial primary completion date:  SPIRALE: Study During Pregnancy of Expression of miRNAs in RA or SLE (clinicaltrials.gov) -  Mar 7, 2019   
    P=N/A,  N=50, Completed, 
    Active, not recruiting --> Completed Recruiting --> Completed | Trial completion date: Jul 2019 --> Oct 2018 | Trial primary completion date: Jul 2019 --> Oct 2018